Revelation Biosciences doses first patient in PRIME phase 1b study of Gemini in CKD patients: San Diego, California Friday, February 28, 2025, 18:00 Hrs [IST] Revelation Bioscienc ...

Data from the PRIME clinical study will support future development in both the GEM-CKD and GEM-AKI programs. AKI, also known as acute renal failure, is defined as a rapid loss of kidney function.

Data from the PRIME clinical study will support future development in both the GEM-CKD and GEM-AKI programs. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

Data from the PRIME clinical study will support future development in both the GEM-CKD and GEM-AKI programs. Gemini is being developed for multiple indications including as a pretreatment to ...

Proton has officially launched the locally assembled (CKD) Proton Saga in Cairo, Egypt, and has commenced sales of Malaysia’s ...